Compare REX AI Equity Premium Income ETF (AIPI) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Charles River Laboratories Intl. Inc — how do they compare? REX AI Equity Premium Income ETF trades at $36.35, while Charles River Laboratories Intl. Inc trades at $223.4 (market cap $11.01B). The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AIPI | CRL | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $231.43 |
52-Week Low | $32.45 | $145.57 |
Market Cap | — | $11.01B |
Enterprise Value | — | $13.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.10, up 1.87% with neutral technical signals. The ETF maintains a high weekly dividend distribution strategy, recently transitioning to weekly payouts. Technical analysis shows mixed signals with bullish moving averages but neutral oscillators, trading near key support at $37. Recent news highlights concerns about NAV erosion risk despite the attractive yield structure.
The outlook remains cautious due to structural limitations in the option-writing strategy that caps upside potential. While the ~34.8% yield appears attractive, sustainability depends heavily on AI market momentum. Investors face NAV erosion risk if technology sector performance falters, requiring careful monitoring of the fund's premium income strategy effectiveness.
CRL trades at $228.68, down 0.87% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported negative net income of -$144.34M in 2025 despite revenue stability around $4.02B, resulting in a high P/E of 684.85. Recent earnings beats and strategic collaborations, such as with Lilly TuneLab (Business Wire, 2026-06-18), highlight operational strengths amid profitability challenges.
Outlook is mixed: strong analyst support (72% buy ratings) and positive cash flow trends contrast with negative margins and high debt. Key risks include sustained unprofitability and competitive pressures, but institutional confidence and technical momentum suggest potential for recovery if earnings improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
